How to Launch a Biotech for Individualized Therapies: Lessons from the Mila Story

Introduction

Eight years ago, Julia Vitarello’s daughter Mila received a bespoke medicine designed specifically for her unique genetic mutation. Inspired by that success, Vitarello is now launching a new biotech company to create these individualized therapies at scale—but her journey reveals the real challenges any entrepreneur must face. This step-by-step guide shows what it takes to start a biotech focused on personalized medicines, from identifying a rare mutation to securing the right funding and regulatory buy-in.

What You Need

• A well-characterized patient mutation (preferably with a clear molecular mechanism)
• Scientific collaborators (molecular biologists, geneticists, clinicians)
• Legal and regulatory expertise (FDA consultant or in-house counsel)
• Initial seed funding (angel investors, grants, or venture capital)
• Laboratory or contract research organization (CRO) for preclinical work
• Patient advocacy network or community support
• A scalable platform for designing and manufacturing customized therapies

Step-by-Step Guide

Step 1: Identify a Compelling Patient Story with a Well-Defined Mutation

Your journey begins with a specific patient whose disease-causing mutation can be targeted. In Mila’s case, the mutation was a highly specific genetic error that could be addressed with a custom antisense oligonucleotide. Without a clearly defined genetic target, bespoke medicine is impossible. Engage with clinicians and genetic counselors to find such patients and document their medical history thoroughly.

Step 2: Validate the Scientific Approach Preclinically

Before moving toward human trials, you must show that your designed therapy works in cell lines or animal models. Collaborate with academic labs or CROs to test your candidate. For Mila’s medicine, preclinical data demonstrated that the oligonucleotide could compensate for the mutation. This evidence is critical to convince regulators and investors that your approach is viable.

Step 3: Navigate Regulatory Pathways Early

The FDA has released guidance encouraging customized therapies, but as Julia Vitarello learned with EveryONE Medicines, that guidance may not go far enough to satisfy investors. Engage with the FDA early through pre-IND meetings or orphan drug designation requests. Understand the specific requirements for N-of-1 trials and what evidence the agency expects. A clear regulatory strategy can make or break your company’s credibility.

Step 4: Secure Funding with a Realistic Business Model

Investors need to see a path to return on investment. Because each bespoke medicine is made for one patient, the economics are challenging. Vitarello’s previous company folded partly because FDA guidance didn’t give investors enough confidence. To avoid that, pitch a platform that can produce multiple customized therapies more efficiently, reducing costs. Consider non-dilutive funding from patient foundations, grants, or strategic partnerships with larger biopharma companies.

Step 5: Build a Scalable Platform

You cannot handcraft each therapy de novo. Develop a technology platform—such as modular antisense oligonucleotide design or gene editing—that allows you to rapidly convert a new mutation sequence into a therapeutic candidate. Automate the design, synthesis, and testing processes. This scalability is what attracted Vitarello to start a new company after EveryONE Medicines folded.

Step 6: Engage Patient Communities and Advocacy Groups

Patient families are often your most passionate supporters and can help with fundraising, clinical trial recruitment, and raising awareness. Vitarello herself is a powerful advocate because of her daughter Mila. Establish a nonprofit or partner with existing rare disease foundations to build trust and gather resources. Community pressure can also influence regulatory agencies and investors to pay attention.

Tips for Success

• Start with a single case that proves feasibility. Mila’s story demonstrated that an individualized medicine could be made. Build momentum around one high-impact story.
• Use FDA guidance as a floor, not a ceiling. The agency's guidance on customized therapies is a starting point; work with regulators to define what evidence is sufficient for your program.
• Design your business model for scalability early. Investors will ask how one patient can become 10, 100, or more. Be ready with a platform answer.
• Maintain strong patient-family relationships. The emotional connection to a real person like Mila can sustain you through setbacks and keep your mission focused.
• Plan for the possibility that one company may not succeed. Vitarello folded EveryONE Medicines but is starting again. Learn from failure and iterate.
• Document every step for potential publication. Publishing your methods and results can attract collaborators and strengthen your regulatory submissions.

By following these steps and heeding the lessons from Julia Vitarello’s journey, you can increase your chances of building a biotech that brings life-saving personalized medicines to patients who have no other options.